Matches in Nanopublications for { <http://bio2rdf.org/drugbank:DB05241> ?p ?o ?g. }
Showing items 1 to 12 of
12
with 100 items per page.
- drugbank:DB05241 type drugbank_vocabulary:Drug assertion.
- drugbank:DB05241 label "XL765 [drugbank:DB05241]" assertion.
- drugbank:DB05241 seeAlso DB05241 assertion.
- drugbank:DB05241 description "XL765 is an orally available small molecule that has been shown in preclinical studies to selectively inhibit the activity of phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR). It is being developed by Exelixis, Inc." assertion.
- drugbank:DB05241 identifier "drugbank:DB05241" assertion.
- drugbank:DB05241 title "XL765" assertion.
- drugbank:DB05241 drugbank_vocabulary:x-cas cas: assertion.
- drugbank:DB05241 drugbank_vocabulary:drugbank-id "DB05241" assertion.
- drugbank:DB05241 bio2rdf_vocabulary:x-identifiers.org DB05241 assertion.
- drugbank:DB05241 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB05241" assertion.
- drugbank:DB05241 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB05241 bio2rdf_vocabulary:identifier "DB05241" assertion.